Abstract
Peru implemented strict social distancing measures during the early phase of the epidemic and is now experiencing one of the largest CoVID-19 epidemics in Latin America. Estimates of disease severity are an essential indicator to inform policy decisions about the intensity and duration of interventions needed to mitigate the outbreak. Here we derive delay-adjusted case fatality rates (aCFR) of CoVID-19 in a middle-income country in South America.
We used government-reported time series of CoVID-19 cases and deaths stratified by age group and gender.
Our estimates as of May 25, 2020, of the aCFR for men and women are 10.8% (95%CrI: 10.5–11.1%) and 6.5% (95%CrI: 6.2–6.8%), respectively, and an overall aCFR of 9.1% (95%CrI: 8.9–9.3%). Our results show that senior individuals are the most severely affected by CoVID-19, particularly men, with aCFR of almost 60% for those aged 80-years. We found that men have a significantly higher cumulative morbidity ratio than women across most age groups (proportion test, p-value< 0.001), with the exception of those aged 0–9 years.
The COVID-19 epidemic is imposing a large mortality burden in Peru. Senior individuals, especially those who are older than 70 years of age, are being disproportionately affected by the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant Number 20H03940]; the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan to [KM]; National Science Foundation NSF [grant 1414374] as part of the joint NSF-National Institutes of Health NIH-United States Department of Agriculture USDA Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences Research Council [grant BB/M008894/1] to [GC]; and the ANID Millennium Science Initiative/ Millennium Initiative for Collaborative Research on Bacterial Resistance, MICROB-R, [NCN17_081] to [EU].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the Ministry of Health in Peru. Data was anonymized prior to the authors gaining access. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of the Ministry of Health in Peru.